164 related articles for article (PubMed ID: 30718315)
21. Patterns of adjuvant radiation usage and survival outcomes for stage I endometrial carcinoma in a large hospital-based cohort.
Wong AT; Rineer J; Schwartz D; Weiner J; Safdieh J; Choi K; Schreiber D
Gynecol Oncol; 2017 Jan; 144(1):113-118. PubMed ID: 27823769
[TBL] [Abstract][Full Text] [Related]
22. Patterns of Care, Predictors, and Outcomes of Adjuvant Therapy for Early- and Advanced-Stage Uterine Clear Cell Carcinoma: A Population-Based Analysis.
Gockley AA; Rauh-Hain JA; Anders AM; Meyer LA; Clemmer J; Lu KH; Clark RM; Schorge JO; del Carmen MG
Int J Gynecol Cancer; 2016 May; 26(4):697-704. PubMed ID: 26825834
[TBL] [Abstract][Full Text] [Related]
23. Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus.
Hong JC; Foote J; Broadwater G; Gaillard S; Havrilesky LJ; Chino JP
Int J Gynecol Cancer; 2017 May; 27(4):720-729. PubMed ID: 28375927
[TBL] [Abstract][Full Text] [Related]
24. Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma.
Xiang M; English DP; Kidd EA
Gynecol Oncol; 2019 Sep; 154(3):487-494. PubMed ID: 31257010
[TBL] [Abstract][Full Text] [Related]
25. Management for Elderly Women With Advanced-Stage, High-Grade Endometrial Cancer.
Rauh-Hain JA; Pepin KJ; Meyer LA; Clemmer JT; Lu KH; Rice LW; Uppal S; Schorge JO; Del Carmen MG
Obstet Gynecol; 2015 Dec; 126(6):1198-1206. PubMed ID: 26551187
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional study.
Mahdi H; Rose PG; Elshaikh MA; Munkarah A; Isrow D; Singh S; Waggoner S; Ali-Fehmi R; Morris RT; Harding J; DeBenardo R
Gynecol Oncol; 2015 Mar; 136(3):529-33. PubMed ID: 25575483
[TBL] [Abstract][Full Text] [Related]
27. Treatment of vaginal recurrences in endometrial carcinoma by high-dose-rate brachytherapy.
Sorbe B; Söderström K
Anticancer Res; 2013 Jan; 33(1):241-7. PubMed ID: 23267151
[TBL] [Abstract][Full Text] [Related]
28. Salvage high-dose-rate brachytherapy and external beam radiotherapy for isolated vaginal recurrences of endometrial cancer with no prior adjuvant therapy.
Chapman CH; Maghsoudi K; Littell RD; Chen LM; Hsu IC
Brachytherapy; 2017; 16(6):1152-1158. PubMed ID: 28802913
[TBL] [Abstract][Full Text] [Related]
29. Overuse of external beam radiotherapy for stage I endometrial cancer.
Wright JD; Margolis B; Hou JY; Burke WM; Tergas AI; Huang Y; Hu JC; Ananth CV; Neugut AI; Hershman DL
Am J Obstet Gynecol; 2016 Jul; 215(1):75.e1-7. PubMed ID: 26875941
[TBL] [Abstract][Full Text] [Related]
30. Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy.
Pacaut C; Bourmaud A; Rivoirard R; Moriceau G; Guy JB; Collard O; Bosacki C; Jacquin JP; Levy A; Chauleur C; Magné N; Merrouche Y
Am J Clin Oncol; 2015 Jun; 38(3):272-7. PubMed ID: 23751320
[TBL] [Abstract][Full Text] [Related]
31. Survival advantage associated with multimodal therapy in women with node-positive (stage-IIIC) uterine papillary serous carcinoma: a National Cancer Database study.
Lin JF; Muñiz K; Sukumvanich P; Gehrig P; Beriwal S; Kelley JL; Edwards RP; Olawaiye AB
BJOG; 2016 Oct; 123(11):1846-52. PubMed ID: 26537059
[TBL] [Abstract][Full Text] [Related]
32. Survival of women with Mullerian adenosarcoma: A National Cancer Data Base study.
Seagle BL; Kanis M; Strohl AE; Shahabi S
Gynecol Oncol; 2016 Dec; 143(3):636-641. PubMed ID: 27771166
[TBL] [Abstract][Full Text] [Related]
33. Racial Disparities in the Receipt of Guideline Care and Cancer Deaths for Women with Ovarian Cancer.
Cronin KA; Howlader N; Stevens JL; Trimble EL; Harlan LC; Warren JL
Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):539-545. PubMed ID: 30487136
[TBL] [Abstract][Full Text] [Related]
34. Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study.
Seagle BL; Sobecki-Rausch J; Strohl AE; Shilpi A; Grace A; Shahabi S
Gynecol Oncol; 2017 Apr; 145(1):61-70. PubMed ID: 28317559
[TBL] [Abstract][Full Text] [Related]
35. The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: A multi-institutional pooled analysis.
Qu XM; Velker VM; Leung E; Kwon JS; Elshaikh MA; Kong I; Logie NA; Mendez LC; van der Putten LJ; Donovan EK; Munkarah AR; Wiebe EM; Parra-Herran C; Warner A; Louie AV; D'Souza DP
Gynecol Oncol; 2018 May; 149(2):283-290. PubMed ID: 29544706
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors.
Landrum LM; Nugent EK; Zuna RE; Syzek E; Mannel RS; Moore KN; Walker JL; McMeekin DS
Gynecol Oncol; 2014 Jan; 132(1):50-4. PubMed ID: 24219982
[TBL] [Abstract][Full Text] [Related]
37. Patterns of Adjuvant Therapy Utilization in Uterine Carcinosarcoma Stages I to III: A National Cancer Database Analysis.
Stokes WA; Robin TP; Jackson MW; Amini A; Schefter TE; Lefkowits CC; Fisher CM
Am J Clin Oncol; 2018 Oct; 41(10):927-932. PubMed ID: 28654573
[TBL] [Abstract][Full Text] [Related]
38. Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma.
Sood BM; Jones J; Gupta S; Khabele D; Guha C; Runowicz C; Goldberg G; Fields A; Anderson P; Vikram B
Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):208-16. PubMed ID: 12909235
[TBL] [Abstract][Full Text] [Related]
39. Trends in Treatment of Uterine Serous Cancer in the Medicare Population.
Rauh-Hain JA; Connor SC; Clemmer JT; Foley OW; Clark RM; Hall TR; Boruta DM; Schorge JO; del Carmen MG
Int J Gynecol Cancer; 2015 Jul; 25(6):1023-30. PubMed ID: 25914960
[TBL] [Abstract][Full Text] [Related]
40. Postoperative vaginal brachytherapy alone is the treatment of choice for grade 1-2, stage IC endometrial cancer.
Cengiz M; Singh AK; Grigsby PW
Int J Gynecol Cancer; 2005; 15(5):926-31. PubMed ID: 16174247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
